6 курс / Кардиология / СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ

Литература

207.Doehner W., Bunck A.C., Rauchhaus M. et al. Secretory sphin; gomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body compo; sition, muscular functional capacity, and peripheral blood flow // Eur. Heart J. – 2007. – Vol. 28. – P. 821–828.

208.Dollery C.M., McEwan J.R., Henney A.M. Matrix metalloprotein; ases and cardiovascular disease // Circ. Res. – 1995. – Vol. 77.

– P. 863–868.

209.Donohuel A., Sarail M., Isobe S. et al. J. Narulal Imaging apopto; sis in myocardial infarction with 111 In;labelled Annexin A5 // J. Nucl. Cardiol. – 2007. – Vol. 14 (2). – P. S61–S61.

210.Douvaras P., Antonatos D.G., Kekou K. et al. Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction // Cardiology. – 2009. – Vol. 114 (1). – Р. 11–18.

211.Downie P.F., Talwar S., Squire I.B. et al. Prolonged stability of endogenous cardiotrophin;1 in whole blood // Metabolism. – 2001. – Vol. 50. – P. 237–240.

212.Duchen M.R. Roles of mitochondria in health and disease // Dia; betes. – 2004. – Vol. 53, suppl. 1. – P. S96–S102.

213.Dumont P., Leu J.I., Delia Pietra A.C. et al. The codon 72 poly; morphic variants of p53 have markedly different apoptotic po; tential // J. Nat. Genet. – 2003. – Vol. 33 (3). – P. 357–365.

214.Economou E., Farmakis D., Stefanadis C. Elevated circulating levels of the soluble from Fas/APO;1, an important cofactor to the activation of apoptosis, in chronic heart failure // Eur. Heart J. – 1998. – Vol. 19. – P. 468.

215.Eltyeb A., Graham S. Apoptosis in chronic heart failure // Cardi; ology. – 2007. – Vol. 114 (3). – Р. 375–379.

216.Esposito F., Mathieu;Costello O., Entin P.L. et al. The skeletal muscle VEGF mRNA response to acute exercise in patients with chronic heart failure // Growth Factors. – 2010. – Vol. 28 (2). – Р. 139–147.

217.Faida O., Said A., Samir P. et al NT;proBNP levels, as predictor

369

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

of left ventricular systolic and diastolic dysfunction in patients with chronic heart failure // Int. J. Collaborat. Res. Internal Med; icine & Public Health. – 2012. – Vol. 4 (6). – Р. 910–923.

218.Felker G.M., Shaw L.K., O’Connor C.M. A standardized defini; tion of ischemic cardiomyopathy for use in clinical research // J. Am. Coll. Cardiol. – 2002. – Vol. 39. – Р. 210–218.

219.Ferdinandy P., Schulz R. Nitric oxide, superoxide, and peroxyni; trite in myocardial ischemia;reperfusion injury and precondition; ing // Br. J. Pharmacol. – 2003. – Vol. 138. – Р. 532–543.

220.Fernandes H., Koneru B., Fernandes N. et al. Investigation of promoter polymorphisms in the tumor necrosis factor;alpha and interleukin;10 genes in liver transplantant petients // Transplan; tation. – 2002. – Vol. 73 (12). – P. 1886–1891.

221.Ferrara N. Role of vascular endothelial growth factor in regula; tion of physiological angiogenesis // Am. J. Physiol. Cell Physiol.

–2001. – Vol. 280. – P. 1358–1366.

222.Ferrari R., Guardigli G., Mele D. et al. Oxidative stress during myocardial ischaemia and heart failure // Curr. Pharm. Des. – 2004. – Vol. 10. – Р. 1699–1711.

223.Force T.L. Heart failure: molecules, mechanisms and therapeu; tic targets // Circulation. – 2007. – Vol. 115. – P. 347.

224.Fortuno A., San Jose G., Moreno M.U. et al. Oxidative stress and vascular remodeling // Exp. Physiol. – 2005. – Vol. 90. – Р. 457– 462.

225.Fortuno M.A., Gonzalez A., Ravassa S. et al. Clinical implications of apoptosis in hypertensive heart disease // Am. J. Physiol. Heart Circ. Physiol. – 2003. – Vol. 284. – P. 1495–1506.

226.Frechette J.P., Martineau I., Gagnon G. Platelet rich plasmas: growth factor content and roles in wound healing // J. Dent. Res.

–2005. – Vol. 84. – Р. 434–439.

227.Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms // Cytokine Growth Factor Rev. – 2004. – Vol. 15. – Р. 197–204.

370

Литература

228.Freedman S.B., Isner J.M. Therapeutic angiogenesis for coro; nary artery disease // Ann. Intern. Med. – 2002. – Vol. 136. –

Р.54–71.

229.Fuchs S., Lavi I., Tzang O. et al. Intracoronary monocyte chemoat; tractant protein 1 and vascular endothelial growth factor levels are associated with necrotic core, calcium and fibrous tissue ath; erosclerotic plaque components: an intracoronary ultrasound radiofrequency study // Cardiology. – 2012. – Vol. 123 (2). –

Р.125–132.

230.Funalot B., Courbon D., Brousseau T. et al. Genes encoding en; dothelinconverting enzyme;1 and endothelin;1 interact to influ; ence blood pressure in women: the EVA study // J. Hypertens. – 2004. – Vol. 22 (4). – Р. 739–743.

231.Gaasch W.H., Delorey D.E., St John Sutton M.G. et al. Patterns of structural and functional remodeling of the left ventricle in chronic heart failure // Am. J. Cardiol. – 2008. – Vol. 102. –

Р.459–462.

232.Gang L., Huhua L., Liangming W. Serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic conges; tive heart failure // Clin. Med. Sci. J. – 2002. – Vol. 17 (4). –

Р.258.

233.Garg S., Narula J., Chandrashekhar Y. Apoptosis and heart fail; ure: clinical relevance and therapeutic target // J. Mol. Cell. Car; diol. – 2005. – Vol. 38. – P. 73–79.

234.Gerhardt H., Golding M., Fruttiger M. et al. VEGF guides angio; genic sprouting utilizing endothelial tip cell filopodia // J. Cell. Biol. – 2003. – Vol. 161. – Р. 1163–1177.

235.Glaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals // Genes. Dev. – 1998.

– Vol. 12. – Р. 2973–2983.

236.Gobe G., Browning J., Howard T. et al. Apoptosis occurs in en; dothelial cells during hypertension;induced microvascular rar; efaction // J. Sructur. Biol. – 1997. – Vol. 118. – Р. 63–72.

237.Gonzalez;Conejero R., Lozano M.L., Rivera J. et al. Polymor;

371

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

phisms of platelet membrane glycoprotein Ibα associated with arterial thrombotic disease // Blood. – 1998. – Vol. 92. – P. 2771– 2776.

238.Gospodarowicz D. Fibroblast growth factor. Chemical structure and biologic function // Clin. Orthop. Relat. Res. – 1990. – Vol. 257. – Р. 231–248.

239.Gottlieb R.A., Burleson K.O., Kloner R.A. et al. Reperfusion inju; ry induces apoptosis in rabbit cardiomyocytes // J. Clin. Invest.

–1994. – Vol. 94. – P. 1621–1628.

240.Gradman A., Deedwania P., Cody R. et al. Predictors of total mor; tality and sudden death in mild to moderate heart failure // J. Am. Coll. Cardiol. – 1989. –Vol. 14. – Р 564–570.

241.Grewal J., McKelvie R.S., Persson H. et al. Usefulness of N;ter; minal pro;brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction // Am. J. Cardiol.

–2008. – Vol. 102 (6). – Р. 733–737.

242.Griendling K.K., FitzGerald G.F. Oxidative stress and cardiovas; cular injury. Part I: Basic mechanisms and in vivo monitoring of ROS // Circulation. – 2003. – Vol. 108. – Р. 1912–1916.

243.Gruson D., Lepoutre T., Ketelslegers J.M. et al. C;terminal FGF23 is a strong predictor of survival in systolic heart failure // Pep; tides. – 2012. – Vol. 37. – Р. 258–262.

244.Grybauskiene R., Karciauskaite D., Brazdzionyte J. et al. Brain natriuretic peptide and other cardiac markers predicting left ven; tricular remodeling and function two years after myocardial inf; arction // Medicina (Kaunas). – 2007. – Vol. 43, No. 9. – P. 708– 715.

245.Grzela T., Odak M., Jowak J. et al. Induction of apoptosis by re; ceptors for factors from the TNF family // Postery Hig. Med. Sur.

–1999. – Vol. 53 (2). – P. 351–363.

246.Gustafsson A.B., Gottlieb R.A. Bcl;2 family members and apop; tosis, taken to heart // Am. J. Physiol. Cell Physiol. – 2007. – Vol. 292. – P. C45–C51.

372

Литература

247.Gustafsson T., Bodin K., Sylvйn C. et al. Increased expression of VEGF following exercise training in patients with heart failure // Eur. J. Clin. Invest. – 2001. – Vol. 31 (4). – Р. 362–366.

248.Guttormsen A.B., Ueland P.M., Nesthus I. et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>or=40 micromol/liter). The Hordaland Homocysteine Study //

J.Clin. Invest. – 1996. – Vol. 98 (9). – Р. 2174–2183.

249.Hai;Feng T., Wei W., Yuan;Yuan Y. et al. Association between poly; morphisms in IL;16 genes and coronary heart disease risk // Pak.

J.Med. Sci. – 2013. – Vol. 29 (4). – P. 1033–1037.

250.Hamanishi T., Fyryta H., Kato H. et al. Functional variants in the glutathione peroxidase;1 (GPx;1) gene are associated with in; creased intima;media thickness of carotid arteries and risk of macrovascular disease in Japanese type 2 diabetic patients // Diabetes. – 2004. – Vol. 53. – Р. 2455–2460.

251.Han H., Long H., Wang H. et al. Progressive apoptotic cell death triggered by transient oxidative insult in H9c2 rat ventricular cells: a novel pattern of apoptosis and the mechanisms // Am. J. Phys; iol. Heart Circ. Physiol. – 2004. – Vol. 286. – P. H2169–H2182.

252.Hashimoto S., Nagai S., Sese J. et al. Gene expression profile in human leukocytes // Blood. – 2003. – Vol. 101. – P. 3509–3513.

253.Haunstetter A., Izumo S. Toward аntiapoptosis as a new treat; ment modality // Circ. Res. – 2000. – Vol. 86. – P. 371–376.

254.Hausenloy D.J., Yellon D.M. The mitochondrial permeability tran; sition pore: its fundamental role in mediating cell death during ischaemia and reperfusion // J. Mol. Cell Cardiol. – 2003. – Vol. 35. – P. 339–341.

255.Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases // Annu. Rev. Pharmacol. Toxicol. – 2005. – Vol. 45. – Р. 51–88.

256.Haynes W.G., Webb D.J. Endothelin as a regulation of cardio; vascular function in health and disease // J. Hypertens. – 1998.

– Vol. 16. – P. 1081–1098.

257.Hellstrom M., Kaien M., Lindahl P.A. et al. Role of PDGF;B and PDGFR;beta in recruitment of vascular smooth muscle cells and

373

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

pericytes during embryonic blood vessel for mation in the mouse

// Development. – 1999. – Vol. 126. – P. 3047–3055.

258.Henriksen P.A., Newby D.E. Therapeutic inhibition of tumour ne; crosis factor α in patients with heart failure: cooling an inflamed heart // Heart. – 2003. – Vol. 89. – P. 14–18.

259.Herzog E., Gu A., Kohmoto T. Early activation of metalloprotein; ases after experimental myocardial infarction occurs in infarct and non;infarct zones // Cardiovasc. Pathol. – 1998. – Vol. 7. – P. 307–312.

260.Hickson;Bick D.L.M., Sparagna G.C., Buja L.M. et al. Palmitate; induced apoptosis in neonatal cardiomyocytes is not dependent on the generation of ROS // Am. J. Physiol. Heart Circ. Physiol. – 2002. – Vol. 282. – P. H656–H664.

261.Hill M.F., Singal P.K. Antioxidant and oxidative stress changes failure subsequent to myocardial infarction in rats // Am. J. Pathol.

– 1996. – Vol. 148 (1). – Р. 291–300.

262.Hirsch D., Pantely G. Therapeutic angiogenesis: just the basic fact(or)s, please // J. Am. Coll. Cardiol. – 1997. – Vol. 29 (5). – Р. 1107–1108.

263.Hoekstra R., Eskens F.A.L.M., Verweij J. Matrix metalloprotein; ase inhibitors: current developments and future perspectives // The Oncologist. – 2001. – Vol. 6 (5). – P. 415–427.

264.Hogg N., Browning J., Howard T. et al. Apoptosis in vascular en; dothelial cells caused by serum deprivation, oxidative stress and transforming growth factor;beta // Endothelium. – 1999. – Vol. 7. – Р. 35–49.

265.Hojo Y., Ikeda U., Ueno S. et al. Expression of matrix metallopro; teinases in patients with acute myocardial infarction // Jpn. Circ. J. – 2001. – Vol. 65. – P. 71–75.

266.Holly T.A., Drincik A., Byun Y. et al. Caspase inhibition reduces myocute cell death induced by mitochondrial ischemia and rep; erfusion in vivo // J. Mol. Cell. Cardiol. – 1999. – Vol. 31. – P. 1709–1715.

267.Holmes D.I., Zachary I. The vascular endothelial growth factor

374

Литература

(VEGF) family: angiogenic factors in health and disease // Ge; nome Biol. – 2005. – Vol. 6 (2). – Р. 209–219.

268.Horio T. Heart failure and circulatory peptides // Nippon Naika Gakkai Zasshi. – 2005. – Vol. 94. – P. 201–207.

269.Houck K.A., Leung D.W., Rowland A.M. et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms // J. Biol. Chem. – 1992. – Vol. 267 (36).

–P. 26031–26037.

270.Hudson M.P., Armstrong P.W., Ruzyllo W. et al. Effects of selec; tive matrix metalloproteinase inhibitor (PG;116800) to prevent ventricular remodeling after myocardial infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial // J. Am. Coll. Cardiol. – 2006. – Vol. 48. – Р. 15–20.

271.Humphries S.E., Martin S., Cooper J. et al. Interaction between smoking and the stromelysin;1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men // Ann. Hum. Genet. – 2002. – Vol. 66 (5–6). – P. 343–352.

272.Hunt J.M., Aru G.M., Hayden M.R. et al. Induction of oxidative stress and disintegrin metalloproteinase in human heart end– stage failure // Am. J. Physiol. Lung Cell. Mol. Physiol. – 2002. – Vol. 283 (2). – Р. 239–245.

273.Huntley B.K., Ichiki T., Sangaralingham S.J. et al. B;type natri; uretic peptide and extracellular matrix protein interactions in hu; man cardiac fibroblasts // J. Cell Physiol. – 2010. – Vol. 225 (1).

–Р. 251–255.

274.Inoue N., Kawashima S., Kanazawa K. et al. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease // Circulation. – 1998. – Vol. 97 (2). – Р. 135–137.

275.Isner J.M., Kearney M., Bortman S. et al. Apoptosis in human atherosclerosis and restenosis // Circulation. – 1995. – Vol. 91 (11). – Р. 2703–2711.

276.Isner J.M., Vale P., Losordo D.W et al. Angiogenesis and cardio; vascular disease // Dialogues in Cardiovasc. Med. – 2001. – Vol. 6 (3). – Р. 145–170.

375

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

277.Iversen P.O., Woldbaek P.R., Toennessen T. et al. Apoptosis of hematopoietic progenitor cells and increased activation of the TNFa/Fas death pathway within the mouse bone marrow in con; gestive heart failure // Eur. Heart J. – 2001. – Vol. 22, Abstr. Suppl. – P. 397.

278.Jackson G., Gibbs C.R., Davies M.K. et al. ABC of heart failure // Pathophysiology. BMJ. – 2000. – Vol. 320. – P. 167–170.

279.Janicke R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase;3 is required for DNA fragmentation and morfological changes as; sociated with apoptosis // J. Biol. Chem. – 1998. – Vol. 273. – Р. 9357–9360.

280.Jeremias I., Kupatt C., Martin;Villalba A. et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia // Circu; lation. – 2000. – Vol. 102. – P. 915–920.

281.Jernberg T., James S., Lindahl B. et al. NT;proBNP in unstable coronary artery disease;experiences from the FAST, CUSTO IV and FRISC II trials // Eur. J. Heart Fail. – 2004. – Vol. 6 (3). – P. 319–325.

282.Joashi U., Tibby S.M., Turner C. et al. Soluble Fas may be a proin; flammatory marker after cardiopulmonary bypass in children // J. Thorac. Cardiovasc. Surg. – 2002. – Vol. 123. – Р. 137–144.

283.Jones L.C. Genetic regulation of endothelial function // Heart. – 2005. – Vol. 91, No. 10. – Р. 1275–1277.

284.Jortani S.A., Prabhu S.D., Valdes R. Strategies for developing biomarkers of heart failure // Clin. Chem. – 2004. – Vol. 50. – P. 265–278.

285.Judge D.P., Johnson N.M., Cirino A.L. et al. Heart failure and ge; nomics // J. Am. Coll. Cardiol. – 2007. – Vol. 49. – P. 1106.

286.Juul K. Genetically reduced antioxidative protection and in; creased ischemic heart disease risk: the Copenhagen City Heart Study // Circulation. – 2003. – Vol. 109, No. 1. – Р. 59–65.

287.Kang J., Gu Y., Li P. et al. PDGF;a as an epicardial mitogen during heart development // Dev. Dyn. – 2008. – Vol. 237. – Р. 692– 701.

376

Литература

288.Kang P.M., Izumo S. Apoptosis and heart failure. A critical review of the literature // Circ. Res. – 2000. – Vol. 86. – P. 1107–1113.

289.Kannan K., Jain S.K. Oxidative stress and apoptosis // Patho; physiology. – 2000. – Vol. 7 (3). – Р. 153–163.

290.Kannel W.B. Left ventricular hypertrophy as a risk factor in arteri; al hypertension // Eur. Heart J. – 1996. – Vol. 13. – Р. 82–88.

291.Kapoun A.M., Liang F., O’Young G. et al. B;type natriuretic pep; tide exerts broad functional opposition to transforming growth factor;beta in primary human cardiac fibroblasts: fibrosis, myo; fibroblast conversion, proliferation, and inflammation // Circ. Res.

– 2004. – Vol. 94 (4). – Р. 453–461.

292.Kasama S., Furuya M., Toyama T. et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute my; ocardial infarction // Eur. Heart J. – 2008. – Vol. 29 (12). – P. 1485– 1494.

293.Keyt B.A., Nguyen H.V., Berleau L.T. et al. Identification of vas; cular endothelial growth factor determinants for binding KDR and FLT;1 receptors. Generation of receptor;selective VEGF variants by site;directed mutagenesis // J. Biol. Chem. – 1996. – Vol. 271 (10). – Р. 5638–5646.

294.Khan I.A. Role of endothelin;1 in acute myocardial infarction // Chest. – 2005. – Vol. 127. – P. 1474–1476.

295.Kim R.J., Becker R.C. Association between factor V Leiden, pro; thrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta;analysis of published studies // Am. Heart J. – 2003. – Vol. 146 (6). – Р. 948–957.

296.Kimura I., Honda R., Okai H. et al. Vascular endothelial growth factor promotes cell;cycle transition from G0 to G1 phase in sub; cultured endothelial cells of diabetic rat thoracic aorta // Jpn. J. Pharmacol. – 2000. – Vol. 83 (l). – Р. 47–55.

297.Kimura K., Hashiguchi T., Deguchi T. et al. Serum VEGF;as a prog; nostic factor of atherosclerosis // Atherosclerosis. – 2007. – Vol. 194. – P. 182–188.

377

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

298.Kitsios G., Zintzaras E. Genetic variation associated with ischemic heart failure: a HuGE review and meta;analysis // Am. J. Epide; miol. – 2007. – Vol. 166 (6). – P. 619;633.

299.Klagsbrun M. The fibroblast growth factor family: structural and biological properties // Progr. Growth Factor Res. – 1989. – Vol. 1. – Р. 207–226.

300.Klerk M., Verhoef P., Clarke R. et al. MTHFR Studies Collabora; tion Group. MTHFR 677C>T polymorphism and risk of coronary heart disease: a meta;analysis // JAMA. – 2002. – Vol. 288 (16).

– Р. 2023–2031.

301.Koren M.J., Devereux R.B., Casale P.N. et al. Relation of left ven; tricular mass and geometry to morbidity and mortality in uncom; plicated essential hypertension // Ann. Intern. Med. – 1991. – Vol. 114. – P. 345–352.

302.Korf;Klingebiel M., Kempf T., Schluter K.D. et al. Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial inf; arction // Circulation. – 2011. – Vol. 123. – Р. 504–514.

303.Kramer P. The CD95 (APO;1/Fas) receptor/ligand system – death signals and diseases // Cell Death Differ. – 1996. – Vol. 3. – Р. 159–160.

304.Ku D.D., Zaleski J.K., Litu S., Brock T.A. Vascular endothelial growth factor induces EDRF;dependent relaxation in coronary arteries // Am. J. Physiol. – 1993. – Vol. 265. – P. 586–592.

305.Kubota T., Miyagishima M., Alvarez R.J. et al. Expression of proin; flammatory cytokines in the failing human heart: comparison of recent;onset and end;stage congestive heart failure // J. Heart Lung Transplant. – 2000. – Vol. 19, No. 9. – P. 819–824.

306.Kuhn M. Molecular physiology of natriuretic peptide signaling // Basic Res. Cardiol. – 2004. – Vol. 99. – Р. 76–82.

307.Kwak H.B. Effects of aging and exercise training on apoptosis in the heart // J. Exerc. Rehabil. – 2013. – Vol. 9 (2). – P. 212–219.

308.Lainchbury J.G., Troughton R.W., Strangman K.M, et al. N;ter; minal pro;B;type natriuretic peptide;guided treatment for chronic

378